Characteristics of patients at screening
| Patient characteristics at screening . | All patients(n = 42) . |
|---|---|
| Age | |
| Median (range), n (%) | 64 (43-75) |
| ≤65 | 22 (52) |
| 66-74 | 19 (45) |
| ≥75 | 1 (3) |
| Sex, n (%) | |
| Male | 23 (55) |
| Female | 19 (45) |
| Race, n (%) | |
| White | 37 (88) |
| Black or African American | 2 (5) |
| Hispanic | 1 (2) |
| Other | 2 (5) |
| ECOG performance status, n (%) | |
| 0 | 6 (14) |
| 1 | 35 (83) |
| 2 | 1 (2) |
| ISS disease stage, n (%) | |
| I | 15 (36) |
| II | 9 (21) |
| III | 11 (26) |
| Unknown | 7 (17) |
| Median time since initial diagnosis of MM | |
| Years (range) | 5 (1-19) |
| Number of prior lines of therapy, n (%) (range) | 3 (1-11) |
| 1 | 6 (14) |
| 2 | 8 (19) |
| 3 | 9 (21) |
| 4 | 3 (7) |
| ≥5 | 16 (38) |
| Types of prior therapies, n (%) | |
| Bortezomib | 36 (86) |
| Carfilzomib | 7 (17) |
| Ixazomib | 3 (7) |
| Lenalidomide | 22 (52) |
| Pomalidomide | 19 (45) |
| Thalidomide | 5 (12) |
| Anti-CD38 antibody | 5 (12) |
| Glucocorticoid | 42 (100) |
| Alkylating agent | 38 (90) |
| Anthracyline | 7 (17) |
| Autologous stem cell transplant | 30 (71) |
| Disease refractory to, n (%) | |
| PI | 21 (50) |
| Immunomodulatory drug | 34 (81) |
| Anti-CD38 antibody | 5 (12) |
| PI and immunomodulatory drug | 19 (45) |
| Cytogenetics, n (%) | |
| Standard risk | 20 (48) |
| High risk | |
| del(17p)° | 3 (7) |
| del(4;14)° | 1 (2) |
| del(14;16)° | 0 (0) |
| Unknown | 18 (43) |
| History of peripheral neuropathy, n (%) | |
| No | 22 (52) |
| Yes | 20 (48) |
| Ongoing peripheral neuropathy at screening, n (%) | |
| Grade 1 | 18 (43) |
| Grade 2 | 1 (2) |
| Unknown grade | 1 (2) |
| Patient characteristics at screening . | All patients(n = 42) . |
|---|---|
| Age | |
| Median (range), n (%) | 64 (43-75) |
| ≤65 | 22 (52) |
| 66-74 | 19 (45) |
| ≥75 | 1 (3) |
| Sex, n (%) | |
| Male | 23 (55) |
| Female | 19 (45) |
| Race, n (%) | |
| White | 37 (88) |
| Black or African American | 2 (5) |
| Hispanic | 1 (2) |
| Other | 2 (5) |
| ECOG performance status, n (%) | |
| 0 | 6 (14) |
| 1 | 35 (83) |
| 2 | 1 (2) |
| ISS disease stage, n (%) | |
| I | 15 (36) |
| II | 9 (21) |
| III | 11 (26) |
| Unknown | 7 (17) |
| Median time since initial diagnosis of MM | |
| Years (range) | 5 (1-19) |
| Number of prior lines of therapy, n (%) (range) | 3 (1-11) |
| 1 | 6 (14) |
| 2 | 8 (19) |
| 3 | 9 (21) |
| 4 | 3 (7) |
| ≥5 | 16 (38) |
| Types of prior therapies, n (%) | |
| Bortezomib | 36 (86) |
| Carfilzomib | 7 (17) |
| Ixazomib | 3 (7) |
| Lenalidomide | 22 (52) |
| Pomalidomide | 19 (45) |
| Thalidomide | 5 (12) |
| Anti-CD38 antibody | 5 (12) |
| Glucocorticoid | 42 (100) |
| Alkylating agent | 38 (90) |
| Anthracyline | 7 (17) |
| Autologous stem cell transplant | 30 (71) |
| Disease refractory to, n (%) | |
| PI | 21 (50) |
| Immunomodulatory drug | 34 (81) |
| Anti-CD38 antibody | 5 (12) |
| PI and immunomodulatory drug | 19 (45) |
| Cytogenetics, n (%) | |
| Standard risk | 20 (48) |
| High risk | |
| del(17p)° | 3 (7) |
| del(4;14)° | 1 (2) |
| del(14;16)° | 0 (0) |
| Unknown | 18 (43) |
| History of peripheral neuropathy, n (%) | |
| No | 22 (52) |
| Yes | 20 (48) |
| Ongoing peripheral neuropathy at screening, n (%) | |
| Grade 1 | 18 (43) |
| Grade 2 | 1 (2) |
| Unknown grade | 1 (2) |
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.